Download PDF
Semin Thromb Hemost 2011; 37(7): 723-729
DOI: 10.1055/s-0031-1297162
© Thieme Medical Publishers

The Coagulation System in Children: Developmental and Pathophysiological Considerations

Vera Ignjatovic1 , Eliza Mertyn2 , Paul Monagle2 , 3
  • 1Department of Haematology Research, Murdoch Childrens Research Institute, Australia
  • 2Department of Paediatrics, University of Melbourne, Australia
  • 3Department of Clinical Haematology, University of Melbourne, Royal Children's Hospital, Victoria, Australia
Further Information

Publication History

Publication Date:
20 December 2011 (online)

   Permissions and Reprints
Preview

ABSTRACT

The coagulation system in children is complex and ever changing, a fact encapsulated in the term developmental hemostasis. Studies confirm that there are quantitative and almost certainly qualitative differences in the coagulation system with age, and the control of these changes comes from something external to the liver. What remains uncertain is the magnitude of the qualitative changes and the implications of the changes for the growing child. At the very least, developmental hemostasis probably provides a protective mechanism for neonates and children and hence contributes to the decreased risk of thromboembolic and/or hemorrhagic events in these age groups. In addition, developmental hemostasis could also reflect the role that hemostatic proteins play in physiological development and hence the demand of other processes, such as angiogenesis. Finally, without doubt, developmental hemostasis affects the interactions of anticoagulant drugs with the coagulation system. This article will initially discuss the most recent evidence with respect to qualitative age-related changes in the coagulation system. Subsequently the article will discuss the coagulation system during childhood in light of the three aforementioned areas of clinical impact and suggest possible strategies to further understand this complex and exciting field of study.

KEYWORDS

Development - coagulation - plasma proteins - thromboembolism - children

REFERENCES

  • 1 Monagle P, Ignjatovic V, Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas.  Blood Rev. 2010;  24 (2) 63-68
    Search in Google Scholar
  • 2 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant.  Am J Pediatr Hematol Oncol. 1990;  12 (1) 95-104
    Search in Google Scholar
  • 3 Andrew M, Paes B, Milner R et al.. Development of the human coagulation system in the full-term infant.  Blood. 1987;  70 (1) 165-172
    Search in Google Scholar
  • 4 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood.  Blood. 1992;  80 (8) 1998-2005
    Search in Google Scholar
  • 5 Monagle P, Barnes C, Ignjatovic V et al.. Developmental haemostasis. Impact for clinical haemostasis laboratories.  Thromb Haemost. 2006;  95 (2) 362-372
    Search in Google Scholar
  • 6 Monagle P, Chan A, de Veber G, Massicotte P. Developmental Hemostasis. Pediatric Thromboembolism and Stroke Handbook. 3rd ed. Hamilton, Ontario: BC Decker Inc.; 2006: 3-30
    Search in Google Scholar
  • 7 Ignjatovic V, Lai C, Summerhayes R et al.. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults.  PLoS ONE. 2011;  6 (2) e17213
    Search in Google Scholar
  • 8 Mari D, Mannucci P M, Coppola R, Bottasso B, Bauer K A, Rosenberg R D. Hypercoagulability in centenarians: the paradox of successful aging.  Blood. 1995;  85 (11) 3144-3149
    Search in Google Scholar
  • 9 Bock SC. Antithrombin III and heparin cofactor II. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 321-334
    Search in Google Scholar
  • 10 Monagle P, Hagstrom J. Developmental haemostasis. In: Fetal and Neonatal Physiology. 3rd ed. St. Louis: Elsevier; 2003: 1435-1447
    Search in Google Scholar
  • 11 Witt I, Müller H. Phosphorus and hexose content of human foetal fibrinogen.  Biochim Biophys Acta. 1970;  221 (2) 402-404
    Search in Google Scholar
  • 12 Hamulyák K, Nieuwenhuizen W, Devilée P P, Hemker H C. Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns.  Thromb Res. 1983;  32 (3) 301-310
    Search in Google Scholar
  • 13 Witt I, Müller H, Künzer W. Evidence for the existence of foetal fibrinogen.  Thromb Diath Haemorrh. 1969;  22 (1) 101-109
    Search in Google Scholar
  • 14 Miller B E, Tosone S R, Guzzetta N A, Miller J L, Brosius K K. Fibrinogen in children undergoing cardiac surgery: is it effective?.  Anesth Analg. 2004;  99 (5) 1341-1346
    Search in Google Scholar
  • 15 Martinez J, MacDonald K A, Palascak J E. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.  Blood. 1983;  61 (6) 1196-1202
    Search in Google Scholar
  • 16 Dang C V, Shin C K, Bell W R, Nagaswami C, Weisel J W. Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly.  J Biol Chem. 1989;  264 (25) 15104-15108
    Search in Google Scholar
  • 17 Ignjatovic V, Ilhan A, Monagle P. Evidence for age-related differences in human fibrinogen.  Blood Coagul Fibrinolysis. 2011;  22 (2) 110-117
    Search in Google Scholar
  • 18 Manco-Johnson M J, Spedale S, Peters M et al.. Identification of a unique form of protein C in the ovine fetus: developmentally linked transition to the adult form.  Pediatr Res. 1995;  37 (3) 365-372
    Search in Google Scholar
  • 19 Niessen R W, Lamping R J, Peters M, Lamers W H, Sturk A. Fetal and neonatal development of antithrombin III plasma activity and liver messenger RNA levels in sheep.  Pediatr Res. 1996;  39 (4 Pt 1) 685-691
    Search in Google Scholar
  • 20 Lisman T, Platto M, Meijers J C, Haagsma E B, Colledan M, Porte R J. The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver.  Blood. 2011;  117 (6) 2070-2072
    Search in Google Scholar
  • 21 Mosnier L O, Zlokovic B V, Griffin J H. The cytoprotective protein C pathway.  Blood. 2007;  109 (8) 3161-3172
    Search in Google Scholar
  • 22 Taylor Jr F B, Kinasewitz G T. The diagnosis and management of disseminated intravascular coagulation.  Curr Hematol Rep. 2002;  1 (1) 34-40
    Search in Google Scholar
  • 23 Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin.  Thromb Haemost. 1994;  72 (6) 836-842
    Search in Google Scholar
  • 24 Gibson B E, Chalmers E, Bolton-Maggs P, Henderson D J, Lynn R. Thrombembolism in childhood: a prospective 2 year BPSU study in the United Kingdom.  Thromb Haemost. 2003;  1 (Suppl 1) OC422
    Search in Google Scholar
  • 25 Massicotte P, Leaker M, Marzinotto V et al.. Enhanced thrombin regulation during warfarin therapy in children compared to adults.  Thromb Haemost. 1998;  80 (4) 570-574
    Search in Google Scholar
  • 26 Mitchell L G, Andrew M, Hanna K Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA) et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.  Cancer. 2003;  97 (2) 508-516
    Search in Google Scholar
  • 27 Monagle P, Adams M, Mahoney M et al.. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry.  Pediatr Res. 2000;  47 (6) 763-766
    Search in Google Scholar
  • 28 Newall F, Wallace T, Crock C et al.. Venous thromboembolic disease: a single-centre case series study.  J Paediatr Child Health. 2006;  42 (12) 803-807
    Search in Google Scholar
  • 29 Nowak-Göttl U, Heinecke A, von Kries R, Nürnberger W, Münchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.  Thromb Res. 2001;  103 (3) 165-172
    Search in Google Scholar
  • 30 Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey.  Arch Dis Child Fetal Neonatal Ed. 1997;  76 (3) F163-F167
    Search in Google Scholar
  • 31 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry.  Pediatrics. 1995;  96 (5 Pt 1) 939-943
    Search in Google Scholar
  • 32 van Ommen C H, Heijboer H, Büller H R, Hirasing R A, Heijmans H S, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.  J Pediatr. 2001;  139 (5) 676-681
    Search in Google Scholar
  • 33 White R H. The epidemiology of venous thromboembolism.  Circulation. 2003;  107 (23, Suppl 1) I4-I8
    Search in Google Scholar
  • 34 Kuhle S, Massicotte P, Chan A et al.. Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service.  Thromb Haemost. 2004;  92 (4) 722-728
    Search in Google Scholar
  • 35 Raffini L, Huang Y S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007.  Pediatrics. 2009;  124 (4) 1001-1008
    Search in Google Scholar
  • 36 Bjarke B, Herin P, Blombäck M. Neonatal aortic thrombosis. A possible clinical manifestation of congenital antithrombin 3 deficiency.  Acta Paediatr Scand. 1974;  63 (2) 297-301
    Search in Google Scholar
  • 37 De Stefano V, Leone G, Ferrelli R et al.. Severe deep vein thrombosis in a 2-year-old child with protein S deficiency.  Thromb Haemost. 1987;  58 (4) 1089
    Search in Google Scholar
  • 38 Israels S J, Seshia S S. Childhood stroke associated with protein C or S deficiency.  J Pediatr. 1987;  111 (4) 562-564
    Search in Google Scholar
  • 39 Mannino F L, Trauner D A. Stroke in neonates.  J Pediatr. 1983;  102 (4) 605-610
    Search in Google Scholar
  • 40 Shapiro M E, Rodvien R, Bauer K A, Salzman E W. Acute aortic thrombosis in antithrombin III deficiency.  JAMA. 1981;  245 (17) 1759-1761
    Search in Google Scholar
  • 41 Andrassy K, Ritz E, Bommer J. Hypercoagulability in the nephrotic syndrome.  Klin Wochenschr. 1980;  58 (19) 1029-1036
    Search in Google Scholar
  • 42 Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia.  Thromb Diath Haemorrh. 1970;  24 (3) 562-571
    Search in Google Scholar
  • 43 Kauffmann R H, Veltkamp J J, Van Tilburg N H, Van Es L A. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome.  Am J Med. 1978;  65 (4) 607-613
    Search in Google Scholar
  • 44 Kuhlmann U, Blättler W, Pouliadis G, Siegenthaler W. [Complications of nephrotic syndrome with special reference to thromboembolic accidents].  Schweiz Med Wochenschr. 1979;  109 (6) 200-209
    Search in Google Scholar
  • 45 Schrader J, Köstering H, Züchner C, Kaiser H, Kramer P, Scheler F. Antithrombin III-Bestimmungim Schnelltest: Ein Vergleich mit Partigen-Platten undeinem chromogenen Substrat.  Lab Med. 1981;  5 211-218
    Search in Google Scholar
  • 46 Thaler E, Balzar E, Kopsa H, Pinggera W F. Acquired antithrombin III deficiency in patients with glomerular proteinuria.  Haemostasis. 1978;  7 (5) 257-272
    Search in Google Scholar
  • 47 Hirsh J. Heparin.  N Engl J Med. 1991;  324 (22) 1565-1574
    Search in Google Scholar
  • 48 Olson S T, Björk I, Shore J D. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin.  Methods Enzymol. 1993;  222 525-559
    Search in Google Scholar
  • 49 Carrell R W, Stein P E, Fermi G, Wardell M R. Biological implications of a 3 A structure of dimeric antithrombin.  Structure. 1994;  2 (4) 257-270
    Search in Google Scholar
  • 50 Schreuder H A, de Boer B, Dijkema R et al.. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions.  Nat Struct Biol. 1994;  1 (1) 48-54
    Search in Google Scholar
  • 51 Levi M. All heparins are equal, but some are more equal than others.  J Thromb Haemost. 2003;  1 (5) 884-885
    Search in Google Scholar
  • 52 Schedin-Weiss S, Richard B, Hjelm R, Olson S T. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence.  Biochemistry. 2008;  47 (51) 13610-13619
    Search in Google Scholar
  • 53 Chan A K, Berry L R, Paredes N, Parmar N. Isoform composition of antithrombin in a covalent antithrombin-heparin complex.  Biochem Biophys Res Commun. 2003;  309 (4) 986-991
    Search in Google Scholar
  • 54 Picard V, Ersdal-Badju E, Bock S C. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity.  Biochemistry. 1995;  34 (26) 8433-8440
    Search in Google Scholar
  • 55 Carlson T H, Atencio A C, Simon T L. Comparison of the behaviour in vivo of two molecular forms of antithrombin III.  Biochem J. 1985;  225 (3) 557-564
    Search in Google Scholar
  • 56 Witmer M R, Hatton M W. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo.  Arterioscler Thromb. 1991;  11 (3) 530-539
    Search in Google Scholar
  • 57 Turk B, Brieditis I, Bock S C, Olson S T, Björk I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.  Biochemistry. 1997;  36 (22) 6682-6691
    Search in Google Scholar
  • 58 Schedin-Weiss S, Richard B, Hjelm R, Olson S T. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence.  Biochemistry. 2008;  47 (51) 13610-13619
    Search in Google Scholar
  • 59 Adcock D M, Fink L M, Marlar R A, Cavallo F, Zangari M. The hemostatic system and malignancy.  Clin Lymphoma Myeloma. 2008;  8 (4) 230-236
    Search in Google Scholar
  • 60 Akl E A, van Doormaal F F, Barba M et al.. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation.  Cochrane Database Syst Rev. 2007;  (3) CD006652
    Search in Google Scholar
  • 61 Wojtukiewicz M Z, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer.  Semin Thromb Hemost. 2004;  30 (1) 5-20
    Search in Google Scholar
  • 62 Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome.  Am J Respir Crit Care Med. 1998;  158 (2) 470-476
    Search in Google Scholar
  • 63 Ganrot P O. Inhibition of plasmin activity by alpha-2-macroglobulin.  Clin Chim Acta. 1967;  16 (2) 328-329
    Search in Google Scholar
  • 64 Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation.  J Biol Chem. 1989;  264 (20) 11539-11542
    Search in Google Scholar
  • 65 Blacker D, Wilcox M A, Laird N M et al.. Alpha-2 macroglobulin is genetically associated with Alzheimer disease.  Nat Genet. 1998;  19 (4) 357-360
    Search in Google Scholar
  • 66 Baker A H, Edwards D R, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities.  J Cell Sci. 2002;  115 (Pt 19) 3719-3727
    Search in Google Scholar
  • 67 French K, Yerbury J J, Wilson M R. Protease activation of alpha2-macroglobulin modulates a chaperone-like action with broad specificity.  Biochemistry. 2008;  47 (4) 1176-1185
    Search in Google Scholar
  • 68 Andrew M, Paes B, Milner R et al.. Development of the human coagulation system in the healthy premature infant.  Blood. 1988;  72 (5) 1651-1657
    Search in Google Scholar
  • 69 Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children.  Blood. 1991;  78 (9) 2299-2304
    Search in Google Scholar
  • 70 Schmidt B, Mitchell L, Ofosu F A, Andrew M. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma.  Thromb Haemost. 1989;  62 (4) 1074-1077
    Search in Google Scholar
  • 71 Ignjatovic V, Greenway A, Summerhayes R, Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis.  Br J Haematol. 2007;  138 (3) 366-368
    Search in Google Scholar
  • 72 Ling X, Delorme M, Berry L et al.. alpha 2-Macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces.  Pediatr Res. 1995;  37 (3) 373-378
    Search in Google Scholar
  • 73 Guzzetta N A, Miller B E, Todd K et al.. Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease.  Anesth Analg. 2006;  103 (5) 1131-1138
    Search in Google Scholar
  • 74 Albisetti M, Chan A K, McCrindle B W, Wong D, Monagle P, Andrew M. Impaired fibrinolytic activity is present in children with dyslipidemias.  Pediatr Res. 2004;  55 (4) 576-580
    Search in Google Scholar
  • 75 Ignjatovic V, Furmedge J, Newall F et al.. Age-related differences in heparin response.  Thromb Res. 2006;  118 (6) 741-745
    Search in Google Scholar
  • 76 Ignjatovic V, Summerhayes R, Newall F, Monagle P T. The in vitro response to low-molecular-weight heparin is not age-dependent in children.  Thromb Haemost. 2010;  103 (4) 855-856
    Search in Google Scholar
  • 77 Newall F, Ignjatovic V, Summerhayes R et al.. In vivo age dependency of unfractionated heparin in infants and children.  Thromb Res. 2009;  123 (5) 710-714
    Search in Google Scholar
  • 78 Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins.  J Thromb Haemost. 2010;  8 (6) 1290-1294
    Search in Google Scholar
  • 79 Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan M R. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs.  Thromb Res. 1988;  52 (6) 517-527
    Search in Google Scholar
  • 80 McDonald M M, Jacobson L J, Hay Jr W W, Hathaway W E. Heparin clearance in the newborn.  Pediatr Res. 1981;  15 (7) 1015-1018
    Search in Google Scholar
  • 81 Turner Gomes S, Nitschmann E, Benson L, Burrows P, Andrew M. Heparin is cleared faster in children with congenital heart disease than adults.  J Am Coll Cardiol. 1993;  21 (2) 59a
    Search in Google Scholar
  • 82 Newall F, Ignjatovic V, Johnston L et al.. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin.  Thromb Haemost. 2010;  103 (5) 1085-1090
    Search in Google Scholar
  • 83 Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.  Br J Haematol. 2010;  149 (5) 734-738
    Search in Google Scholar
  • 84 Trame M N, Mitchell L, Krümpel A, Male C, Hempel G, Nowak-Göttl U. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study.  J Thromb Haemost. 2010;  8 (9) 1950-1958
    Search in Google Scholar
  • 85 Andrew M, Marzinotto V, Brooker L A et al.. Oral anticoagulation therapy in pediatric patients: a prospective study.  Thromb Haemost. 1994;  71 (3) 265-269
    Search in Google Scholar
  • 86 Streif W, Andrew M, Marzinotto V et al.. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients.  Blood. 1999;  94 (9) 3007-3014
    Search in Google Scholar
  • 87 Carpentieri U, Nghiem Q X, Harris L C. Clinical experience with an oral anticoagulant in children.  Arch Dis Child. 1976;  51 (6) 445-448
    Search in Google Scholar
  • 88 Doyle J J, Koren G, Cheng M Y, Blanchette V S. Anticoagulation with sodium warfarin in children: effect of a loading regimen.  J Pediatr. 1988;  113 (6) 1095-1097
    Search in Google Scholar
  • 89 Evans D I, Rowlands M, Poller L. Survey of oral anticoagulant treatment in children.  J Clin Pathol. 1992;  45 (8) 707-708
    Search in Google Scholar
  • 90 Bonduel M, Sciuccati G, Hepner M et al.. Acenocoumarol therapy in pediatric patients.  J Thromb Haemost. 2003;  1 (8) 1740-1743
    Search in Google Scholar
  • 91 Piquet P, Losay J, Doubine S. [Acenocoumarol (Sintrom) and fluinidione (Previscan) in pediatrics after cardiac surgical procedures].  Arch Pediatr. 2002;  9 (11) 1137-1144
    Search in Google Scholar

Paul MonagleM.D. M.B.B.S. M.Sc. F.C.C.P. F.R.C.P.A. F.R.A.C.P. 

Professor, Department of Clinical Haematology, Department of Paediatrics, University of Melbourne

Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia

Email: paul.monagle@rch.org.au